PURPOSE: To investigate the association between tumor size and clinicopathologic factors and outcomes of upper urinary tract urothelial carcinoma (UTUC) in patients treated surgically for UTUC. METHODS: A single-center series of 235 consecutive patients who were treated surgically for UTUC between January 1999 and December 2011 was evaluated. Patients with a history of muscle-invasive urothelial carcinoma of the urinary bladder, those who received neoadjuvant therapies, and those with previous contralateral UTUC were excluded. Bladder-only recurrence, any recurrence, and cancer-specific mortality after surgery were analyzed. Recurrence-free probabilities and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method and Cox regression analyses. RESULTS: Tumor size was significantly associated with age of the patient (P = 0.001), tumor location (P < 0.0001), tumor multifocality (P = 0.005), higher tumor stage (P < 0.0001), higher tumor grade (P = 0.038), lymphovascular invasion (P = 0.002), and mode of operation (P = 0.001). Tumor size was not associated with bladder-only recurrence (HR 0.91; 95% CI 0.46-1.80; P = 0.79). The Kaplan-Meier method showed that tumor size >3 cm was significantly associated with worse CSS (P = 0.006, log rank). The 5-year CSS for patients with tumor size ≤ 3 cm was 70.1% and for patients with tumor size >3 cm was 56.1%. Tumor size was not associated with cancer-specific survival in multivariable analysis (HR 1.53; 95% CI 0.89-2.61; P = 0.12). CONCLUSIONS: Tumor size >3 cm was associated with a lower 5-year CSS at Kaplan-Meier analysis, but was not an independent predictor of CSS, bladder-only recurrence, and any recurrence-free survival at multivariable analysis.
PURPOSE: To investigate the association between tumor size and clinicopathologic factors and outcomes of upper urinary tract urothelial carcinoma (UTUC) in patients treated surgically for UTUC. METHODS: A single-center series of 235 consecutive patients who were treated surgically for UTUC between January 1999 and December 2011 was evaluated. Patients with a history of muscle-invasive urothelial carcinoma of the urinary bladder, those who received neoadjuvant therapies, and those with previous contralateral UTUC were excluded. Bladder-only recurrence, any recurrence, and cancer-specific mortality after surgery were analyzed. Recurrence-free probabilities and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method and Cox regression analyses. RESULTS:Tumor size was significantly associated with age of the patient (P = 0.001), tumor location (P < 0.0001), tumor multifocality (P = 0.005), higher tumor stage (P < 0.0001), higher tumor grade (P = 0.038), lymphovascular invasion (P = 0.002), and mode of operation (P = 0.001). Tumor size was not associated with bladder-only recurrence (HR 0.91; 95% CI 0.46-1.80; P = 0.79). The Kaplan-Meier method showed that tumor size >3 cm was significantly associated with worse CSS (P = 0.006, log rank). The 5-year CSS for patients with tumor size ≤ 3 cm was 70.1% and for patients with tumor size >3 cm was 56.1%. Tumor size was not associated with cancer-specific survival in multivariable analysis (HR 1.53; 95% CI 0.89-2.61; P = 0.12). CONCLUSIONS:Tumor size >3 cm was associated with a lower 5-year CSS at Kaplan-Meier analysis, but was not an independent predictor of CSS, bladder-only recurrence, and any recurrence-free survival at multivariable analysis.
Authors: Jay D Raman; Casey K Ng; Douglas S Scherr; Vitaly Margulis; Yair Lotan; Karim Bensalah; Jean-Jacques Patard; Eiji Kikuchi; Francesco Montorsi; Richard Zigeuner; Alon Weizer; Christian Bolenz; Theresa M Koppie; Hendrik Isbarn; Claudio Jeldres; Wareef Kabbani; Mesut Remzi; Mathias Waldert; Christopher G Wood; Marco Roscigno; Mototsuga Oya; Cord Langner; J Stuart Wolf; Philipp Ströbel; Mario Fernández; Pierre Karakiewcz; Shahrokh F Shariat Journal: Eur Urol Date: 2009-07-15 Impact factor: 20.096
Authors: Ping Tan; Jie Chen; Nan Xie; Hang Xu; Jianzhong Ai; Huan Xu; Liangren Liu; Lu Yang; Qiang Wei Journal: Cancer Med Date: 2018-08-27 Impact factor: 4.452
Authors: Camilla Malm; Alexandra Grahn; Georg Jaremko; Bernhard Tribukait; Marianne Brehmer Journal: World J Urol Date: 2019-04-23 Impact factor: 4.226